Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.66 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.62 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.62 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
| ▸ | PPARD | Q03181 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7236617 | 0.91 | SLC13A5 (0.62) | FFAR1SLC13A5MMEMMEL1FFAR4 | |
| SCHEMBL12646406 | 0.87 | SLC13A5 (0.56) | FFAR1SLC13A5MMEMMEL1FFAR4 | |
| SCHEMBL7237789 | 0.86 | FFAR1 (0.55) | FFAR1SLC13A5MMEMMEL1FFAR4 | |
| SCHEMBL4207640 | 0.84 | SLC13A5 (0.60) | FFAR1SLC13A5MMEMMEL1PPARG | |
| SCHEMBL3670702 | 0.84 | FFAR1 (0.76) | FFAR1FFAR4RXRA | |
| SCHEMBL6490922 | 0.84 | FFAR1 (0.58) | FFAR1MMEMMEL1FFAR4PPARD | |
| SCHEMBL7725124 | 0.84 | FFAR1 (0.58) | FFAR1MMEMMEL1FFAR4RXRA | |
| SCHEMBL3992963 | 0.84 | FFAR4 (0.78) | FFAR1FFAR4 | |
| SCHEMBL3671932 | 0.83 | FFAR1 (0.57) | FFAR1FFAR4KEAP1ITGB1ITGA4 | |
| SCHEMBL7234489 | 0.83 | FFAR4 (0.70) | FFAR1MMEL1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | FFAR1 74/4885SLC13A5 1342/4885MME 2898/4885 |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | GPR119, INSR, GPR65 | FFAR1 6/4885SLC13A5 1348/4885MME 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.